Evotec's Crucial April Report: A Test of Credibility

Evotec's annual report in April is a crucial test. Investors await 2026 guidance to see if cost cuts and a biologics deal can forge a real path to profitability.

All eyes are on Evotec as it approaches a pivotal moment in early April. The company is set to release its annual report, but the market's focus will be laser-targeted on the forward-looking guidance for 2026. This forecast will serve as the definitive measure for whether its "Priority Reset" initiative represents a genuine path to profitability or remains merely a cost-cutting exercise.

The share price closed at €5.42 yesterday, reflecting a decline of 9.31% over the preceding 30 days. This downward trend signals that while investors acknowledge the restructuring efforts, they remain unconvinced about the eventual outcome.

Financial Performance: A Mixed Operational Picture

Operational results for the first nine months of 2025 presented a contrasting story. Group revenue reached €535.1 million, marking a 7.1% decrease year-over-year. The early-stage drug discovery and development (D&PD) segment continued to be a challenge, with revenue falling 12.3% to €392.1 million. In contrast, the Just – Evotec Biologics (JEB) unit showed strength, posting an 11.3% increase to €143.4 million.

Profitability, however, remained elusive. The group's adjusted EBITDA stood at -€16.9 million. The period result as of September 30, 2025, was a loss of €118.1 million, an improvement from the prior year's loss of €155.2 million, which the company attributed primarily to lower reorganization expenses.

Cost-Cutting Advances and Strategic Shifts

On a more positive note, Evotec's cost-saving program has exceeded expectations. Savings are running ahead of plan and could total more than €60 million for the full year 2025—double the initial target. The company has also eliminated approximately 280 positions and consolidated sites, aiming to reduce ongoing annual costs by €40 million starting in 2025.

A significant strategic move was the completed sale of the JEB site in Toulouse to Sandoz. The deal includes a perpetual license for continuous biologics manufacturing and carries substantial financial weight: approximately $350 million in cash upfront, plus over $300 million in potential future license fees, development revenue, and success-based milestone payments. This transaction underscores a shift toward a less capital-intensive model, aiming to scale through technology monetization. While logically sound, this strategy does not substitute for the core business demonstrating a return to reliable performance.

The April Litmus Test

The annual report due on April 8, 2026, represents a critical credibility test for management. After several previous forecast disappointments, the market is demanding evidence, not promises. The report must substantiate the "Priority Reset" with concrete assumptions and a robust 2026 outlook that convincingly charts a course toward sustainable profitability.

The company's medium-term ambitions remain high, targeting a revenue compound annual growth rate (CAGR) of 8–12% for the 2024-2028 period and an adjusted EBITDA margin exceeding 20% by 2028.

Analyst opinions are divided. Berenberg and RBC Capital Markets see potential in the leaner corporate structure, setting price targets of €10. Deutsche Bank maintains a more cautious stance with a €6 target.

Recent activity in major shareholdings has also drawn attention. Goldman Sachs crossed the reporting threshold on January 13, 2026, and now holds 6.12% of voting rights (up from 3.68%) through shares and financial instruments. Both Triton GP HoldCo SARL and Mubadala Investment Company also each hold stakes exceeding 5%.

Consequently, the key deliverable for Evotec on April 8 will be a credible 2026 forecast. A convincing plan that translates restructuring progress into a tangible roadmap for profitability could be the catalyst needed to lift the share price back toward its 50-day moving average of €6.06.